Summary of SABCS 2024 Highlights
The San Antonio Breast Cancer Symposium 2024 showcased groundbreaking results from clinical trials and translational research. Here are the key takeaways from our contributions:
1️⃣ PADMA Trial
The PADMA trial results emphasize the superiority of combining endocrine therapy (ET) with CDK4/6 inhibitors over mono-chemotherapy for HR+/HER2- metastatic breast cancer. These findings confirm international guidelines and pave the way for effective, less toxic first-line treatment options.
2️⃣ PENELOPE-B Biomarker Analysis
Serum thymidine kinase activity (TKa) was identified as a dynamic biomarker for early relapse in HR+/HER2- early breast cancer. The study highlights how TKa can be used to monitor residual disease and guide more precise treatment decisions.
3️⃣ BMBC Registry: Biomarkers in Brain Metastases
A subgroup analysis from the BMBC registry revealed significant molecular subtype differences between primary breast tumors and brain metastases. These insights could lead to new diagnostic and therapeutic approaches.
4️⃣ INSEMA Trial
The INSEMA trial demonstrated that omitting sentinel lymph node biopsies (SLNB) in clinically node-negative patients is safe and does not compromise invasive disease-free survival. This marks a milestone in the de-escalation of breast cancer surgery.
5️⃣ Micrometastases After Neoadjuvant Therapy
Our analysis of five major studies highlights the prognostic relevance of micrometastases (ypN1mi). These findings emphasize the need for personalized axillary treatment strategies.
6️⃣ NeoRad Trial
The NeoRad study investigates the efficacy of preoperative radiotherapy compared to standard postoperative radiotherapy. This innovative approach could usher in a new era of personalized radiotherapy for high-risk cases.
7️⃣ PATINA Trial
The combination of Palbociclib with anti-HER2 and endocrine therapy significantly improved progression-free survival in HR+/HER2+ metastatic breast cancer. This represents a new standard in treatment.
8️⃣ GeparDouze Trial
Adding atezolizumab to neoadjuvant chemotherapy improved pathological complete response rates in TNBC. However, the study underscored the need for further biomarker research to identify patients who derive the greatest benefit.
🎉 A heartfelt thank you to all patients, families, researchers, and sponsors who made these advancements possible. Together, we are shaping the future of breast cancer research!
Oral Presentations
Rapid Fire Presentation on December 10, 2024 (18:20 - 18:28 CST):
- PADMA Study (GBG 93)
Primary results of the randomised Phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-/HR+ metastatic breast cancer and indication for chemotherapy - PADMA study
Presenter: S. Loibl
Rapid Fire Presentation on December 12, 2024 (12:10 - 12:15 CST):
- Micrometastasis Analysis (GeparSepto – GBG 69, GeparOcto – GBG 84, GeparNuevo – GBG 89, GeparX – GBG 88, GeparOla – GBG 90)
Surgical axillary intervention after neoadjuvant systemic therapy (NST) for early-stage breast cancer – Clinical significance of micrometastases: data from five neoadjuvant studies
Presenter: J. Holtschmidt
Oral Presentation on December 12, 2024 (10:30 - 10:45 CST)
- INSEMA Study (GBG 75)
No axillary surgery versus axillary sentinel lymph node biopsy in patients with early invasive breast cancer and breast-conserving surgery: Final primary results of the Intergroup-Sentinel-Mamma (INSEMA) trial.
Presenter: T. Reimer
Oral Presentation on December 13, 2024 (10:00 - 10:15 CST)
- GeparDouze Study (GBG 96)
NSABP B-59/GBG-96-GeparDouze: A randomized double-blind Phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant therapy.
Presenter: C. Geyer
Poster Presentations
Poster Presentations on December 11, 2024 (12:00 - 14:00 CST):
- PENELOPE-B Study (GBG 78)
Evaluation of proliferation biomarker serum thymidine kinase activity and prediction of early relapse in HR-positive HER2-negative high-risk early breast cancer.
Presenter: A. Williams - BMBC Study (GBG 79)
Biomarkers in metastatic breast cancer with brain metastases – a subanalysis of matched tumor samples from the BMBC registry.
Presenter: E. Laakmann
Poster Presentation on December 12, 2024 (12:00 - 14:00 CST):
- NeoRad Study (GBG 116)
Preoperative radiotherapy versus postoperative radiotherapy after neoadjuvant chemotherapy in high-risk breast cancer: a prospective, randomized, international multicenter Phase III trial.
Presenter: C. Matuschek
External contributions with GBG participation
Poster Presentation:
1. CAPItello-291: Prevalence of PIK3CA/AKT1/PTEN and other genomic alterations in primary and recurrent tumor tissue: exploratory analysis from the Phase 3 CAPItello-291 clinical trial Presenter: J. Cortés
Date: December 11, 2024 (12:00 - 14:00 CST)
2. CAPItello-291: Capivasertib-fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer who had relapsed or progressed during or after aromatase inhibitor treatment: exploratory analysis of PTEN deficiency by IHC from the phase III CAPItello-291 trial
Presenter: K. Jhaveri
Date: December 11, 2024 (12:00 - 14:00 CST)
3. EvoPAR-Breast01: A randomized phase III study of first-line saruparib (AZD5305) plus camizestrant vs CDK4/6i plus physician’s choice endocrine therapy or plus camizestrant in patients with BRCA1/BRCA2/PALB2 mutations and HR+/HER2− advanced breast cancer
Presenter: P. Razavi
Date: December 11, 2024 (12:00 - 14:00 CST)
Oral Presentation:
4. OlympiA: OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1 and/or BRCA2 pathogenic variants and high risk HER2-negative primary breast cancer: longer term follow-up.
Presenter: J. Garber
Date: December 11, 2024 (GS1: 9:15-11:30 CST)
5. AXSANA/EUBREAST 3: Upstage of N-Stage by Diagnostic Axillary Lymph Node Dissection in Patients w/ Isolated Tumor Cells or Micrometastases in Sentinel/Target Lymph Node after Neoadjuvant Chemotherapy - Results from the Prospective Multicenter AXSANA / EUBREAST 3 Study.
Presenter: T. Kuehn
Date: December 12, 2024 (PS6: 7:00-8:30 CST)
6. AXSANA/EUBREAST 3: Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients – results from the prospective AXSANA registry trial (NCT04373655).
Presenter: S. Hartmann
Date: December 12, 2024 (RF2: 12:00-12:50 CST)
7. ZEST: Circulating Tumor DNA Surveillance in ZEST, a Randomized, Phase 3, Double-Blind Study of Niraparib or Placebo in Patients with Triple Negative Breast Cancer or HER2−, BRCA-Mutated Breast Cancer with Molecular Residual Disease After Definitive Therapy.
Presenter: N. Turner
Date: December 13, 2024 (GS3: 9:00-11:45 CST)
